Dr. Reddy's Laboratories Ltd.
Research Dr. Reddy's Laboratories Ltd. (DRREDDY.NS) on Bullrun: market cap INR 1.03T, P/E 31.0, dividend yield 0.7%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDRREDDY.NS
- ExchangeNSE
- CountryIndia
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyINR
- Market capINR 1.03T
- P/E31.0
- Dividend yield0.7%
- Financial periodQ2 2026
- RevenueINR 80.71B
- Net incomeINR 4.44B
- Free cash flow-INR 4.63B
- Gross margin46.5%
Valuation Snapshot
latest market cap is INR 1.03T; P/E is 31.0; dividend yield is 0.7%.
Peer valuation comparison
Latest P/E is 31.03x versus a Healthcare sector median of 21.74x (42.7% above).
Latest dividend yield is 0.65% versus a Healthcare sector median of 2.4% (72.9% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | INR 1.03T | 31.0 | 0.7% | 8 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 8 INR, yield 0.7%.
About Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Dr. Reddy's Laboratories Ltd.'s market cap?
Dr. Reddy's Laboratories Ltd.'s market capitalization is INR 1.03T.
What is Dr. Reddy's Laboratories Ltd.'s P/E ratio?
Dr. Reddy's Laboratories Ltd.'s price-to-earnings (P/E) ratio is 31.0.
Does Dr. Reddy's Laboratories Ltd. pay a dividend?
Dr. Reddy's Laboratories Ltd. has a dividend yield of 0.7%.
What does Dr. Reddy's Laboratories Ltd. do?
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.